1.41
—
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ikonisys
Its shares trade on Euronext Paris under the ticker ALIKO.PA. It has been listed since 19 July 2021. In the fiscal year to 31 December 2025, it reported revenue of €1.4m and a net loss of €4.2m. At that date it held total assets of €26.7m and shareholders' equity of €19.1m.
Ikonisys SA specializes in the design, manufacture, and distribution of cellular diagnosis applications for cancer, genetic diseases, and fertility problems. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2021-07-19. The firm offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. The company utilizes advanced molecular and immunological markers, Ikoniscope robotic components, software engine, image acquisition, digital microscope and cell detection to design and deliver accurate and reliable detection of rare cells. The company includes clinical diagnostic applications for the diagnosis of different types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH her2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK) and a variety of hematological cancers utilizing the Explorer applications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Jul 2021
- Employees
- 11
Leadership
Pay as last reported
- Mario P. CrovettoChief Executive Officer & Director, since 2022
- Alessandro MauriDirector-Administrative & Finance
- Michael W. Kilpatrick, PhDScientific Director, since 2022
- Bill KochissTechnical Director
- Jurgen Schipper, MBAChief Commercial Officer
- Mario MauriChairman, since 2022
- Mario P. CrovettoChief Executive Officer & Director, since 2022
- Alberto Calvo, MBADirector, since 2022
- Vittorio Grazioli, MDDirector, since 2022
- Roberto Rettani, MBADirector, since 2022
- Pramod K. Srivastava, MD, PhDDirector, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ikonisys SA is headquartered in Paris, Ile-De-France, providing a central operational base.
- The company employs 11 full-time employees to support its specialized health care operations.
- Ikoniscope robotic components and a software engine enable the design of accurate cellular diagnosis applications.
Weaknesses
- The company has a small workforce of only 11 employees, limiting operational scale.
- Ikonisys SA is listed on the Euronext Paris market under the ticker ALIKO.PA, which may restrict capital access.
- The firm's product line is currently focused on specific cancer and genetic disease diagnostics, narrowing its market scope.
Opportunities
- The company can expand its oncoFISH bladder and oncoFISH her2 applications into broader oncology markets.
- Ikonisys SA can leverage its digital microscope and image acquisition technology to develop new fertility testing solutions.
- The firm can utilize its advanced molecular markers to address the detection of genetic disorders in new geographic regions.
Threats
- Competitors in the health care sector may introduce superior image acquisition or cell detection technologies.
- Regulatory changes in France could impact the distribution of Ikonisys SA's clinical diagnostic applications.
- Market volatility on the Euronext Paris exchange could affect the valuation of Ikonisys SA shares.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.